Cargando…

Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction

AIMS: Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intraveno...

Descripción completa

Detalles Bibliográficos
Autores principales: López‐Vilella, Raquel, Lozano‐Edo, Silvia, Arenas Martín, Patricia, Jover‐Pastor, Pablo, Ezzitouny, Meryem, Sorolla Romero, José, Calvo Asensio, María, Martínez‐Solé, Julia, Guerrero Cervera, Borja, Sánchez Martínez, José Carlos, Donoso Trenado, Víctor, Sánchez‐Lázaro, Ignacio, Martinez Dolz, Luis, Almenar Bonet, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788053/
https://www.ncbi.nlm.nih.gov/pubmed/34964300
http://dx.doi.org/10.1002/ehf2.13753
_version_ 1784639476934377472
author López‐Vilella, Raquel
Lozano‐Edo, Silvia
Arenas Martín, Patricia
Jover‐Pastor, Pablo
Ezzitouny, Meryem
Sorolla Romero, José
Calvo Asensio, María
Martínez‐Solé, Julia
Guerrero Cervera, Borja
Sánchez Martínez, José Carlos
Donoso Trenado, Víctor
Sánchez‐Lázaro, Ignacio
Martinez Dolz, Luis
Almenar Bonet, Luis
author_facet López‐Vilella, Raquel
Lozano‐Edo, Silvia
Arenas Martín, Patricia
Jover‐Pastor, Pablo
Ezzitouny, Meryem
Sorolla Romero, José
Calvo Asensio, María
Martínez‐Solé, Julia
Guerrero Cervera, Borja
Sánchez Martínez, José Carlos
Donoso Trenado, Víctor
Sánchez‐Lázaro, Ignacio
Martinez Dolz, Luis
Almenar Bonet, Luis
author_sort López‐Vilella, Raquel
collection PubMed
description AIMS: Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intravenous iron administration according to the type of HF: preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF). METHODS AND RESULTS: We conducted a retrospective, single‐centre study of 565 consecutive outpatients diagnosed with HF, recruited over 5 years, who were given intravenous ferric carboxymaltose (FCM) for the treatment of ID [defined as ferritin < 100 μg/L or ferritin 100–300 μg/L with transferrin saturation (TSAT) < 20%]. Clinical, laboratory, and echocardiographic parameters were analysed before and after administration. After FCM administration, overall ferritin, TSAT, and haemoglobin levels increased up to 5‐fold, 1.6‐fold, and 1.1‐fold, respectively, relative to baseline values in HF patients with reduced and preserved ejection fraction (P < 0.0001), with a greater increase in ferritin and TSAT in HFpEF patients. The left ventricular ejection fraction of the overall series improved by 8 percentage points in both types of HF (from 40% to 48%, P < 0.0001). The percentage of patients with normalization of right ventricular function increased by 6.9 points (from 74.1% to 81%) in HFpEF patients and by 6.4 points (from 53% to 59.4%) in the HFrEF subgroup (P < 0.0001). New York Heart Association functional status slightly improved, from a median of 2.4 (interquartile range, IQR: 2–2.7) to 1.9 (IQR: 1.5–2.5; P < 0.0001) after FCM in both types of HF. No changes were noted in plasma levels of liver enzymes, creatinine, or natriuretic peptide (P > 0.05). CONCLUSIONS: Intravenous iron administration appeared to improve ejection fraction and cardiac functional status in outpatients with ID and HF with both preserved and reduced ejection fraction.
format Online
Article
Text
id pubmed-8788053
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87880532022-01-31 Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction López‐Vilella, Raquel Lozano‐Edo, Silvia Arenas Martín, Patricia Jover‐Pastor, Pablo Ezzitouny, Meryem Sorolla Romero, José Calvo Asensio, María Martínez‐Solé, Julia Guerrero Cervera, Borja Sánchez Martínez, José Carlos Donoso Trenado, Víctor Sánchez‐Lázaro, Ignacio Martinez Dolz, Luis Almenar Bonet, Luis ESC Heart Fail Original Articles AIMS: Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intravenous iron administration according to the type of HF: preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF). METHODS AND RESULTS: We conducted a retrospective, single‐centre study of 565 consecutive outpatients diagnosed with HF, recruited over 5 years, who were given intravenous ferric carboxymaltose (FCM) for the treatment of ID [defined as ferritin < 100 μg/L or ferritin 100–300 μg/L with transferrin saturation (TSAT) < 20%]. Clinical, laboratory, and echocardiographic parameters were analysed before and after administration. After FCM administration, overall ferritin, TSAT, and haemoglobin levels increased up to 5‐fold, 1.6‐fold, and 1.1‐fold, respectively, relative to baseline values in HF patients with reduced and preserved ejection fraction (P < 0.0001), with a greater increase in ferritin and TSAT in HFpEF patients. The left ventricular ejection fraction of the overall series improved by 8 percentage points in both types of HF (from 40% to 48%, P < 0.0001). The percentage of patients with normalization of right ventricular function increased by 6.9 points (from 74.1% to 81%) in HFpEF patients and by 6.4 points (from 53% to 59.4%) in the HFrEF subgroup (P < 0.0001). New York Heart Association functional status slightly improved, from a median of 2.4 (interquartile range, IQR: 2–2.7) to 1.9 (IQR: 1.5–2.5; P < 0.0001) after FCM in both types of HF. No changes were noted in plasma levels of liver enzymes, creatinine, or natriuretic peptide (P > 0.05). CONCLUSIONS: Intravenous iron administration appeared to improve ejection fraction and cardiac functional status in outpatients with ID and HF with both preserved and reduced ejection fraction. John Wiley and Sons Inc. 2021-12-28 /pmc/articles/PMC8788053/ /pubmed/34964300 http://dx.doi.org/10.1002/ehf2.13753 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
López‐Vilella, Raquel
Lozano‐Edo, Silvia
Arenas Martín, Patricia
Jover‐Pastor, Pablo
Ezzitouny, Meryem
Sorolla Romero, José
Calvo Asensio, María
Martínez‐Solé, Julia
Guerrero Cervera, Borja
Sánchez Martínez, José Carlos
Donoso Trenado, Víctor
Sánchez‐Lázaro, Ignacio
Martinez Dolz, Luis
Almenar Bonet, Luis
Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
title Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
title_full Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
title_fullStr Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
title_full_unstemmed Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
title_short Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
title_sort impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788053/
https://www.ncbi.nlm.nih.gov/pubmed/34964300
http://dx.doi.org/10.1002/ehf2.13753
work_keys_str_mv AT lopezvilellaraquel impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT lozanoedosilvia impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT arenasmartinpatricia impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT joverpastorpablo impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT ezzitounymeryem impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT sorollaromerojose impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT calvoasensiomaria impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT martinezsolejulia impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT guerrerocerveraborja impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT sanchezmartinezjosecarlos impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT donosotrenadovictor impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT sanchezlazaroignacio impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT martinezdolzluis impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction
AT almenarbonetluis impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction